

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

**COMP/M.6205 - ELI LILLY / JANSSEN PHARMACEUTICA ANIMAL HEALTH
BUSINESS ASSETS**

SECTION 1.2

Description of the concentration

This notification relates to Eli Lilly and Company's ("Eli Lilly") proposed acquisition of the business of Janssen Animal Health ("JAH") from Janssen Pharmaceutica NV ("Janssen"), a Johnson & Johnson company.

The business activities of the parties are:

- Eli Lilly: discovery, development, manufacture and sale of a range of pharmaceutical products for humans and animals.
- JAH: development and sale of animal health pharmaceuticals targeting disease segments in companion animals and livestock, with special emphasis on swine and poultry.

